Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
India has taken the lead in recognising NAFLD as a major non-communicable disease
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Quinidine Sulphate helps manage rare irregular heartbeat conditions
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated
